Virtual Symposium: Gene Therapy Research in the Age of COVID-19

image iconDuration: 90 minutes

Gene Therapy Research in the Age of COVID-19: Study Startup Success for Infectious Disease, Oncology, and Rare Disease Research

Gene therapy research is expanding rapidly in the clinical setting, especially in oncology, rare diseases, and infectious diseases—in fact, gene therapy research plays a crucial role in responding to the current coronavirus pandemic. The recent outbreak of the novel 2019 coronavirus (2019-nCov or SARS-CoV-2) has led to a surge of interest in coronavirus research. Researchers are working fast to develop medical countermeasures like genetically engineered vaccines. Key study startup obstacles must be addressed within the gene therapy field to keep research moving forward.

In this virtual panel discussion, representatives from industry and academia will explore the unique challenges gene therapy research poses for research sites, sponsors, CROs, and study participants.

Key Takeaways:
  • Optimizing study startup and overcoming obstacles
  • How gene therapy research addresses infectious diseases like coronavirus
  • Impact of manufacturing challenges on study startup

Presented By
Dan Eisenman_symposium.png

Daniel Eisenman

PhD, RBP, SM(NRCM), CBSP
Director, Biosafety Services
Advarra


Meagan Vaughn_symposium.png

Meagan Vaughn

PhD, RAC
Senior Clinical Scientist
Translate Bio


J. Kaitlin Morrison PhD_symposium.png

J. Kaitlin Morrison

PhD
Clinical Development Manager
UNC Lineberger Comprehensive Cancer Center


Andrew Stober_symposium.png

Andrew Stober
Chief Manufacturing Officer
Encoded Therapeutics


Register Now